COR

CENCORA INC

Healthcare • USA

Apr 05 • 04:00PM ET
290.22
+4.25 (+1.49%)
Company Profile

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional he ... read more

Full Time Employees 46,000
Phone 610 727 7000
Website https://www.amerisourcebergen.com
CEO Dr. Robert P. Mauch Ph.D., PharmD
IPO Date 1995-04-04
Sector Healthcare
Industry Medical - Distribution
Address 1 West First Avenue, Conshohocken, PA 19428
Balance Sheet
Total Cash $1,978,061,000
Total Debt $7,856,207,000
Current Ratio 0.87
Quick Ratio 0.48
Profitability
Gross Margin 3.39%
Net Margin 0.55%
ROE 167.19%
ROA 2.38%
ROIC 21.16%
Balance Sheet
Total Cash $1,978,061,000
Total Debt $7,856,207,000
Current Ratio 0.87
Quick Ratio 0.48
Profitability
Gross Margin 3.39%
Net Margin 0.55%
ROE 167.19%
ROA 2.38%
ROIC 21.16%
Name CENCORA INC Sector Healthcare Currency USD Relative Volume 2.59 Market Cap 53984
Current Ratio 0.92 Dividend / Share 2.08 EPS 7.05 Revenue 303192826000 P/S 0.2
P/E 38.7 Beta 0.06 Income 1396220000 Volume 4331378 Average Volume 1674910
Distance to 200DMA 16.03% 200 DMA 239.92 50 DMA 257.37 ROA 2.1 ROE 193.9
Distance to 50DMA 8.17% Return 1Y 14.28% Return YTD 24.19% Forward PE Qtly Growth YOY
Debt/Eq 303.17 P/B 238.3 Dividend Yield 0.9% Net Margin 0.46% Payout Ratio 29.3
Performance
52 Week Range 29.3%
Distance to 200DMA 0.18%
Day Change Percent $0.51
Performance Week $0.51
Performance Month $0.51
Performance Quarter 2024-08-09
Performance YTD $0.51
Performance Year $0.51

Performance Range

Day

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Balance Sheet
Total Cash $3,132,648,000
Total Debt $4,388,076,000
Current Ratio 0.88%
Quick Ratio 0.50%
Profitability
Gross Margin 3.39%
Net Margin 0.55%
ROE 167.19%
ROA 2.38%
ROIC 21.16%
Valuation
Price to Earnings 33.22
Price to Book 55.53
Price to Sales 0.18
Price to Free Cash Flow 15.73
Dividends
Payout Ratio 24.26%
Dividend Yield 0.73%
Dividend Amount $0.51
Last Dividend Pay Date 2024-08-09
Last Dividend Paid $0.51
Performance
52 Week Range 29.3%
Distance to 200DMA 0.18%
Day Change Percent $0.51
Performance Week $0.51
Performance Month $0.51
Performance Quarter 2024-08-09
Performance YTD $0.51
Performance Year $0.51
Company Profile

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional he ... read more

Full Time Employees 46,000
Phone 610 727 7000
Website https://www.amerisourcebergen.com
CEO Dr. Robert P. Mauch Ph.D., PharmD
IPO Date 1995-04-04
Sector Healthcare
Address 1 West First Avenue, Conshohocken, PA 19428
Histogram - Daily

Balance Sheet
Total Cash $3,132,648,000
Total Debt $4,388,076,000
Current Ratio 0.88%
Quick Ratio 0.50%
Profitability
Gross Margin 0.0340%
Net Margin 0.0050%
ROE 1.69%
ROA 0.02%
Company Profile

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional he ... read more

Full Time Employees 46,000
Phone 610 727 7000
Website https://www.amerisourcebergen.com
CEO Dr. Robert P. Mauch Ph.D., PharmD
IPO Date 1995-04-04
Sector Healthcare
Address 1 West First Avenue, Conshohocken, PA 19428
Monthly Win Rate

Balance Sheet (Multi-Column Example)
Dec 2024 Sep 2024 Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023
Cash & Short Term Investments 53,775.0 65,171.0 61,801.0 67,150.0 73,100.0 61,555.0 62,482.0 55,872.0
Receivables 59,306.0 66,243.0 43,172.0 41,150.0 50,102.0 60,985.0 39,186.0 35,899.0
Inventory 6,911.0 7,286.0 6,165.0 6,232.0 6,511.0 6,331.0 7,351.0 7,482.0

Latest News

Here's Why Cencora (COR) is a Strong Momentum Stock
Here's Why Cencora (COR) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

2025-05-09 10:55:52 - zacks.com
Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?
Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

2025-05-08 10:16:10 - zacks.com
Cencora (COR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Cencora (COR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates

2025-05-07 18:00:32 - zacks.com
COR Q2 Earnings & Revenues Beat Estimates, '25 EPS Guidance Raised
COR Q2 Earnings & Revenues Beat Estimates, '25 EPS Guidance Raised

COR's second-quarter fiscal 2025 results showcase a strong segmental performance. The company's earnings guidance for fiscal 2025 looks encouraging.

2025-05-07 14:10:43 - zacks.com
Cencora's Boosts Annual Forecast On Strong Demand For Weight Loss Drugs, Specialty Products Despite Mixed Q2 Earnings
Cencora's Boosts Annual Forecast On Strong Demand For Weight Loss Drugs, Special

Cencora, Inc COR on Wednesday reported second-quarter 2025 sales increased 10.3% to $75.5 billion, missing the consensus of $75.68 billion, primarily due to an 11.4% increase in revenue within the U.S

2025-05-07 14:06:27 - benzinga.com
Cencora, Inc. (COR) Q2 2025 Earnings Call Transcript
Cencora, Inc. (COR) Q2 2025 Earnings Call Transcript

Cencora, Inc. (NYSE:COR ) Q2 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Bennett Murphy - Senior Vice President, Head of Investor Relations & Treasury Bob Mauch - Preside

2025-05-07 10:55:32 - seekingalpha.com
Cencora (COR) Beats Q2 Earnings and Revenue Estimates
Cencora (COR) Beats Q2 Earnings and Revenue Estimates

Cencora (COR) came out with quarterly earnings of $4.42 per share, beating the Zacks Consensus Estimate of $4.08 per share. This compares to earnings of $3.80 per share a year ago.

2025-05-07 08:40:38 - zacks.com
Cencora raises annual profit forecast on strong demand for specialty drugs
Cencora raises annual profit forecast on strong demand for specialty drugs

U.S. drug distributor Cencora raised its annual profit forecast on Wednesday, driven by robust demand for costly specialty medicines and weight-loss drugs.

2025-05-07 07:27:38 - reuters.com
Cencora Reports Fiscal 2025 Second Quarter Results
Cencora Reports Fiscal 2025 Second Quarter Results

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2025 second quarter ended March 31, 2025, revenue increased 10.3 percent year-over-year to $75.5 billion.

2025-05-07 06:30:00 - businesswire.com
MedTech Stocks' Earnings to Watch on May 7: COR, QDEL & INGN
MedTech Stocks' Earnings to Watch on May 7: COR, QDEL & INGN

The medical device sector saw steady sales growth in the first quarter of 2025, supported by innovation in AI, wearables, and personalized care. However, earnings gains were more modest as global tari

2025-05-06 11:15:45 - zacks.com
Camino Announces Exploration Results at Los Chapitos and Further Exploration Plans in Peru
Camino Announces Exploration Results at Los Chapitos and Further Exploration Pla

VANCOUVER, BC / ACCESS Newswire / May 6, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC PINK:CAMZF) (WKN: A116E1) ("Camino" or the "Company") is pleased to announce exploration results at its Coppe

2025-05-06 06:00:00 - accessnewswire.com
Will Speciality and GLP-1 Drugs Help COR Beat Q2 Earnings Estimates?
Will Speciality and GLP-1 Drugs Help COR Beat Q2 Earnings Estimates?

COR's fiscal second-quarter results are likely to reflect decent U.S. Healthcare Solutions segmental performance.

2025-05-05 08:25:29 - zacks.com
Unveiling Cencora (COR) Q2 Outlook: Wall Street Estimates for Key Metrics
Unveiling Cencora (COR) Q2 Outlook: Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Cencora (COR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the qua

2025-05-02 10:20:48 - zacks.com
Cencora (COR) Earnings Expected to Grow: Should You Buy?
Cencora (COR) Earnings Expected to Grow: Should You Buy?

Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2025-04-30 11:08:06 - zacks.com
Will Cencora (COR) Beat Estimates Again in Its Next Earnings Report?
Will Cencora (COR) Beat Estimates Again in Its Next Earnings Report?

Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

2025-04-17 13:15:38 - zacks.com